Index of reports
> Death (21)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Optimark (Gadoversetamide) death. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Optimark side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-10
Patient: male, weighing 91.0 kg (200.2 pounds)
Reactions: Pain, Joint Contracture, Muscle Fibrosis, Muscle Tightness, Myosclerosis, Fatigue, Anhedonia, Joint Range of Motion Decreased, Oedema Peripheral, Depression, Injury, Extremity Contracture, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Anxiety, Emotional Distress, Activities of Daily Living Impaired, Frustration
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: 15 ml, once
Indication: Angiogram
Start date: 2002-10-16
End date: 2002-10-16
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Angiogram
Prohance
Dosage: unk unk, once
Indication: Angiogram
Start date: 2002-10-16
End date: 2002-10-16
Gadolinium IN Unspecified Drug
Indication: Osteomyelitis
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: unk unk, once
Start date: 2005-01-25
End date: 2005-01-25
Omniscan
Indication: Angiogram
Optimark
Indication: Angiogram
Magnevist
Dosage: unk unk, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-11-15
End date: 2002-11-15
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Indication: Diabetic Foot
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-11-05
End date: 2002-11-05
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2005-01-14
End date: 2005-01-14
Magnevist
Dosage: 19 ml, once
Start date: 2004-07-16
End date: 2004-07-16
Other drugs received by patient: Clonidine; Fosrenol; Accupril; Renagel; Phoslo; Diatx; Vitamins NOS; Temazepam; Novolin R; Minoxidil; Insulin [insulin]; Coumadin; Procrit; Lasix
Possible Optimark side effects in 79 year old female
Reported by a physician from United States on 2012-07-20
Patient: 79 year old female, weighing 63.6 kg (140.0 pounds)
Reactions: Skin Wrinkling, Pruritus, Pain, Muscle Rigidity, Erythema, Joint Stiffness, Fatigue, Joint Range of Motion Decreased, Musculoskeletal Stiffness, Oedema, Injury, Extremity Contracture, Skin Hypertrophy, DRY Skin, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Emotional Distress, Anxiety, Arthralgia
Adverse event resulted in: death
Drug(s) suspected as cause:
Omniscan
Dosage: dose reported as eight 20ml vials (160ml)
Start date: 2005-09-20
End date: 2005-09-20
Multihance
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Prohance
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Multihance
Indication: Angiogram
Gadolinium Zeolite
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2001-04-25
End date: 2001-04-25
Gadolinium Zeolite
Start date: 2005-08-16
End date: 2005-08-16
Omniscan
Dosage: route reported as ^first via distal port and then via the proximal port^
Indication: Angiogram
Start date: 2003-12-04
End date: 2003-12-04
Optimark
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2005-08-16
End date: 2005-08-16
Optimark
Indication: Angiogram
Gadolinium Zeolite
Start date: 2001-05-03
End date: 2001-05-03
Magnevist
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2001-04-25
End date: 2001-04-25
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium Zeolite
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2001-03-05
End date: 2001-03-05
Omniscan
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2003-05-23
End date: 2003-05-23
Prohance
Indication: Angiogram
Magnevist
Indication: Angiogram
Start date: 2001-05-03
End date: 2001-05-03
Magnevist
Indication: Nuclear Magnetic Resonance Imaging Brain
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Dosage: dose reported as ^11^ 20ml vials
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-09-01
End date: 2005-09-01
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Other drugs received by patient: Epogen; Imdur; Folic Acid; Potassium Chloride; Lovastatin; Diltiazem; Furosemide; Nephrovite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Renagel; Potassium Chloride; Amiodarone HCL; Hydralazine HCL; Aspirin; Niferex; Coreg; Plendil; Venofer; Zemplar
Possible Optimark side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-18
Patient: male
Reactions: Nephrogenic Systemic Fibrosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Optimark
Possible Optimark side effects in 50 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18
Patient: 50 year old male, weighing 69.8 kg (153.6 pounds)
Reactions: Muscle Contractions Involuntary, Pain, Skin Hyperpigmentation, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Fibrosis, General Physical Health Deterioration, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Induration, Arthralgia, Gait Disturbance, Skin Fibrosis, Mobility Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: 30 ml, once
Start date: 2000-05-05
End date: 2000-05-05
Unspecified Gadolinium Based Contrast Agent
Dosage: unk
Start date: 2006-07-14
End date: 2006-07-14
Magnevist
Dosage: 48 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2000-02-05
End date: 2000-02-05
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Unspecified Gadolinium Based Contrast Agent
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2001-12-17
End date: 2001-12-17
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 39 ml, once
Start date: 2006-07-26
End date: 2006-07-26
Unspecified Gadolinium Based Contrast Agent
Indication: Angiogram
Start date: 2000-10-01
End date: 2000-10-15
Magnevist
Dosage: 40 ml, once
Start date: 2006-08-09
End date: 2006-08-09
Other drugs received by patient: Prednisone; Imuran; Norvasc; Calcium Carbonate; Micardis; Oxycet; Darbepoetin Alfa; Minoxidil; Percocet; Renagel; Digoxin; Clonidine; Phoslo; Lanthanum Carbonate; Ferrlecit; Florinef; Lopressor; Plaquenil; Procardia; Zemplar; Coreg; Amiodarone HCL; Aspirin; Cortisone Acetate; Renaphro; Epogen; Vancomycin; Darbepoetin Alfa; Hectorol; Fosrenol
Possible Optimark side effects in 50 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-18
Patient: 50 year old male, weighing 69.8 kg (153.6 pounds)
Reactions: Muscle Contractions Involuntary, Pain, Skin Hyperpigmentation, Joint Stiffness, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Musculoskeletal Stiffness, Fibrosis, Muscular Weakness, General Physical Health Deterioration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Skin Induration, Arthralgia, Gait Disturbance, Mobility Decreased, Skin Fibrosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Unspecified Gadolinium Based Contrast Agent
Indication: Angiogram
Start date: 2000-10-01
End date: 2000-10-15
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Unspecified Gadolinium Based Contrast Agent
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2001-12-17
End date: 2001-12-17
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 48 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2000-02-05
End date: 2000-02-05
Magnevist
Dosage: 39 ml, once
Start date: 2006-07-26
End date: 2006-07-26
Magnevist
Dosage: 30 ml, once
Start date: 2000-05-05
End date: 2000-05-05
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 40 ml, once
Start date: 2006-08-09
End date: 2006-08-09
Unspecified Gadolinium Based Contrast Agent
Dosage: unk
Start date: 2006-07-14
End date: 2006-07-14
Other drugs received by patient: Epogen; Renagel; Procardia; Aspirin; Lopressor; Minoxidil; Ferrlecit; Zemplar; Coreg; Norvasc; Calcium Carbonate; Lanthanum Carbonate; Renaphro; Imuran; Digoxin; Florinef; Cortisone Acetate; Plaquenil; Micardis; Amiodarone HCL; Darbepoetin Alfa; Prednisone; Hectorol; Vancomycin; Darbepoetin Alfa; Phoslo; Fosrenol; Clonidine; Percocet; Oxycet
Possible Optimark side effects in 82 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-08
Patient: 82 year old female, weighing 69.8 kg (153.7 pounds)
Reactions: Pain, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Induration, Hypoaesthesia, Skin Hyperpigmentation, Deformity, Muscle Tightness, Skin Tightness, Skin Plaque, Pruritus Generalised, Skin Discolouration, Joint Range of Motion Decreased, Oedema Peripheral, Musculoskeletal Stiffness, Asthenia
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Indication: Diagnostic Procedure
Multihance
Indication: Diagnostic Procedure
Contrast Media
Indication: Product Used FOR Unknown Indication
Optimark
Indication: Diagnostic Procedure
Omniscan
Indication: Diagnostic Procedure
Prohance
Indication: Diagnostic Procedure
Other drugs received by patient: Plavix; Hydrochlorothiazide; Xalatan; Meloxicam; Colchicine; Aspirin; Lovenox; Cosopt; Alphagan; Multivitamins and Iron; Cyproheptadine HCL; Amlodipine Besylate and Benazepril HCL; Lotrel
Possible Optimark side effects in 69 year old male
Reported by a physician from United States on 2012-05-08
Patient: 69 year old male, weighing 99.0 kg (217.8 pounds)
Reactions: Pruritus, Joint Contracture, Pain, Joint Stiffness, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Musculoskeletal Stiffness, Fibrosis, Extremity Contracture, Peau D'orange, Nephrogenic Systemic Fibrosis, DRY Skin, Skin Induration, Skin Tightness, Burning Sensation, Gait Disturbance, Asthenia, Cardiovascular Disorder, Skin Fibrosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: unk
Indication: Back Pain
Start date: 2001-03-20
End date: 2001-03-20
Magnevist
Dosage: 10 ml, unk
Indication: Angioplasty
Start date: 2002-10-02
End date: 2002-10-02
Prohance
Indication: Angiogram
Magnevist
Dosage: 10 ml, unk
Start date: 2004-12-02
End date: 2004-12-02
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2002-02-04
End date: 2002-02-04
Optimark
Indication: Angiogram
Multihance
Indication: Angiogram
Magnevist
Dosage: unk
Indication: Angiogram
Start date: 2001-05-17
End date: 2001-05-17
Omniscan
Indication: Angiogram
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 10 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-08-25
End date: 2006-08-25
Magnevist
Dosage: 20 ml, unk
Indication: Stent Placement
Start date: 2003-05-14
End date: 2003-05-14
Magnevist
Dosage: 20 ml, unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2002-03-27
End date: 2002-03-27
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 20 ml, unk
Start date: 2002-09-09
End date: 2002-09-09
Magnevist
Dosage: 20 ml, unk
Start date: 2004-10-19
End date: 2004-10-19
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Other drugs received by patient: Potassium Chloride; Cardura; Aspirin; Norvasc; Demadex; Zetia; Spironolactone; Clonidine; Diltiazem; Epogen; Isosorbide Dinitrate; Quinine Sulfate; Lisinopril; Minoxidil; Nephrocaps
Possible Optimark side effects in 82 year old female
Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-08
Patient: 82 year old female, weighing 69.8 kg (153.7 pounds)
Reactions: Pain, Muscular Weakness, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Hyperpigmentation, Hypoaesthesia, Deformity, Muscle Tightness, Skin Tightness, Skin Plaque, Pruritus Generalised, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Musculoskeletal Stiffness, Asthenia
Adverse event resulted in: death
Drug(s) suspected as cause:
Prohance
Indication: Diagnostic Procedure
Magnevist
Indication: Diagnostic Procedure
Optimark
Indication: Diagnostic Procedure
Multihance
Indication: Diagnostic Procedure
Omniscan
Indication: Diagnostic Procedure
Contrast Media
Indication: Product Used FOR Unknown Indication
Other drugs received by patient: Xalatan; Multivitamins and Iron; Colchicine; Aspirin; Lotrel; Meloxicam; Alphagan; Cosopt; Plavix; Hydrochlorothiazide; Cyproheptadine HCL; Amlodipine Besylate and Benazepril HCL; Lovenox
Possible Optimark side effects in male
Reported by a consumer/non-health professional from United States on 2012-03-22
Patient: male, weighing 91.0 kg (200.2 pounds)
Reactions: Pain, Joint Contracture, Muscle Fibrosis, Muscle Tightness, Myosclerosis, Anhedonia, Fatigue, Joint Range of Motion Decreased, Oedema Peripheral, Depression, Injury, Extremity Contracture, Nephrogenic Systemic Fibrosis, Skin Induration, Skin Tightness, Anxiety, Emotional Distress, Activities of Daily Living Impaired, Frustration
Adverse event resulted in: death
Drug(s) suspected as cause:
Omniscan
Indication: Angiogram
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Angiogram
Prohance
Dosage: unk unk, once
Indication: Angiogram
Start date: 2002-10-16
End date: 2002-10-16
Magnevist
Dosage: 15 ml, once
Indication: Angiogram
Start date: 2002-10-16
End date: 2002-10-16
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 19 ml, once
Start date: 2004-07-16
End date: 2004-07-16
Magnevist
Dosage: unk unk, once
Start date: 2005-01-25
End date: 2005-01-25
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Angiogram
Magnevist
Dosage: unk unk, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-11-15
End date: 2002-11-15
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2002-11-05
End date: 2002-11-05
Other drugs received by patient: Coumadin; Temazepam; Procrit; Fosrenol; Minoxidil; Novolin R; Insulin [insulin]; Phoslo; Diatx; Vitamins NOS; Accupril; Lasix; Clonidine; Renagel
Possible Optimark side effects in female
Reported by a consumer/non-health professional from United States on 2012-03-20
Patient: female
Reactions: Pain, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Fibrosis, Deformity, Scar, Mobility Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Omniscan
Indication: Imaging Procedure
Prohance
Indication: Imaging Procedure
Magnevist
Indication: Imaging Procedure
Optimark
Indication: Imaging Procedure
Multihance
Indication: Imaging Procedure
Possible Optimark side effects in 53 year old female
Reported by a pharmacist from United States on 2012-03-19
Patient: 53 year old female, weighing 114.7 kg (252.4 pounds)
Reactions: Pruritus, Pain, Erythema, Anhedonia, Joint Range of Motion Decreased, Skin Discolouration, Oedema Peripheral, Injury, Pain in Extremity, Localised Oedema, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Skin Tightness, Emotional Distress, Anxiety, Arthralgia, Activities of Daily Living Impaired, Skin Mass, Mobility Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Other drugs received by patient: Xopenex; Vasotec; Demedex; Enalapril; Sensipar; Astelin; Phoslo; Vasopressin; Humulin N; Zelnorm; Ativan; Wellbutrin XL; Aspirin; Santyl; Norco; Keppra; Avandia; Allopurinol; Epogen; Aspirin; Torsemide; Neurontin; Hydrocodone Bitartrate and Acetaminophen; Synthroid; Regular Insulin; Renagel; NPH Insulin; Atrovent; Zyloprim; Mirapex; Glucotrol; Ibuprofen
Possible Optimark side effects in 69 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-28
Patient: 69 year old male, weighing 99.0 kg (217.8 pounds)
Reactions: Pruritus, Pain, Joint Contracture, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Musculoskeletal Stiffness, Fibrosis, Extremity Contracture, Peau D'orange, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Tightness, Burning Sensation, Gait Disturbance, Asthenia, Cardiovascular Disorder, Skin Fibrosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: unk
Indication: Angiogram
Start date: 2001-05-17
End date: 2001-05-17
Magnevist
Dosage: 20 ml, unk
Indication: Stent Placement
Start date: 2003-05-14
End date: 2003-05-14
Magnevist
Dosage: 10 ml, unk
Start date: 2004-12-02
End date: 2004-12-02
Omniscan
Indication: Angiogram
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 20 ml, unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2002-03-27
End date: 2002-03-27
Magnevist
Dosage: 10 ml, unk
Indication: Angioplasty
Start date: 2002-10-02
End date: 2002-10-02
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 20 ml, unk
Start date: 2002-09-09
End date: 2002-09-09
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Angiogram
Magnevist
Dosage: 10 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-08-25
End date: 2006-08-25
Magnevist
Dosage: 20 ml, unk
Start date: 2004-10-19
End date: 2004-10-19
Magnevist
Dosage: unk
Indication: Back Pain
Start date: 2001-03-20
End date: 2001-03-20
Prohance
Indication: Angiogram
Magnevist
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2002-02-04
End date: 2002-02-04
Optimark
Indication: Angiogram
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Other drugs received by patient: Lisinopril; Cardura; Minoxidil; Demadex; Isosorbide Dinitrate
Possible Optimark side effects in female
Reported by a lawyer from United States on 2012-02-27
Patient: female, weighing 93.4 kg (205.5 pounds)
Reactions: Pain, Skin Disorder, Laceration, Muscular Weakness, Skin Induration, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Erythema, Skin Tightness, Arthralgia, Swelling, Musculoskeletal Stiffness, Oedema, Skin Fibrosis, Mobility Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Other drugs received by patient: Humulin N; Monopril; Simvastatin; Coreg; Sular; Aspirin; Darvocet; Renagel
Possible Optimark side effects in female
Reported by a physician from United States on 2012-02-27
Patient: female, weighing 82.4 kg (181.3 pounds)
Reactions: Electrocardiogram ST Segment Depression, Periorbital Cellulitis, Hypertensive Emergency, Electrocardiogram QT Shortened, Angina Unstable, Vascular Graft Thrombosis, Haematemesis, Off Label Use, Ileus, Electrocardiogram T Wave Abnormal, Arteriovenous Fistula Site Complication, Dysphagia, Nausea, Nephrogenic Systemic Fibrosis, Hyperlipidaemia, Renal Failure, Diarrhoea, QRS Axis Abnormal
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Optimark
Dosage: 20 ml, single
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-03-24
End date: 2005-03-24
Prohance
Dosage: 17 ml, single
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2004-04-27
End date: 2004-04-27
Other drugs received by patient: Norvasc; Synthroid; Zemplar; Atacand; Nephrocaps; Epogen; Renagel; Ferrlecit / 00345601 /; Insulin; Catapres / 00171101 /
Possible Optimark side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-01-12
Patient: male, weighing 76.2 kg (167.6 pounds)
Reactions: Emotional Distress, Anhedonia, Arthralgia, Skin Exfoliation, Swelling, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Extremity Contracture
Adverse event resulted in: death
Drug(s) suspected as cause:
Optimark
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Omniscan
Dosage: 20 ml, unk
Indication: Imaging Procedure
Start date: 2003-11-14
End date: 2003-11-14
Magnevist
Dosage: unk
Indication: Imaging Procedure
Start date: 2005-06-17
End date: 2005-06-17
Gadolinium IN Unspecified Drug
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Indication: Endoscopic Retrograde Cholangiopancreatography
Magnevist
Dosage: unk
Start date: 2005-06-28
End date: 2005-06-28
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Arteriogram Coronary
Start date: 1996-05-10
End date: 1996-05-10
Gadolinium IN Unspecified Drug
Other drugs received by patient: Celebrex; Neurontin; Diovan; Lipitor; Hydrocodone Bitartrate; Glucovance; Carvedilol; Levothyroxine Sodium; Diabeta
Possible Optimark side effects in male
Reported by a consumer/non-health professional from United States on 2011-12-12
Patient: male, weighing 99.0 kg (217.8 pounds)
Reactions: Pruritus, Joint Contracture, Pain, Skin Discolouration, Joint Range of Motion Decreased, Skin Lesion, Musculoskeletal Stiffness, Fibrosis, Extremity Contracture, Peau D'orange, Skin Induration, Nephrogenic Systemic Fibrosis, Skin Tightness, Burning Sensation, Gait Disturbance, Cardiovascular Disorder, Asthenia, Skin Fibrosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Start date: 2002-02-04
End date: 2002-02-04
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: unk
Indication: Stent Placement
Start date: 2003-05-14
End date: 2003-05-14
Magnevist
Dosage: unk
Start date: 2004-10-19
End date: 2004-10-19
Optimark
Indication: Angiogram
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: unk
Indication: Angioplasty
Start date: 2002-10-02
End date: 2002-10-02
Magnevist
Dosage: unk
Start date: 2004-12-02
End date: 2004-12-02
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Angiogram
Magnevist
Dosage: 10 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-08-25
End date: 2006-08-25
Prohance
Indication: Angiogram
Omniscan
Indication: Angiogram
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: unk
Indication: Back Pain
Start date: 2001-03-20
End date: 2001-03-20
Magnevist
Dosage: unk
Indication: Angiogram
Start date: 2001-05-17
End date: 2001-05-17
Magnevist
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2002-03-27
End date: 2002-03-27
Magnevist
Dosage: unk
Start date: 2002-09-09
End date: 2002-09-09
Possible Optimark side effects in 42 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-11-15
Patient: 42 year old male, weighing 81.0 kg (178.2 pounds)
Reactions: Skin Exfoliation, Joint Contracture, Pain, Post Inflammatory Pigmentation Change, Neuropathic Arthropathy, Stasis Dermatitis, Anhedonia, Joint Range of Motion Decreased, Skin Ulcer, Oedema, Rash Generalised, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, DRY Skin, Skin Induration, Skin Tightness, Rash Macular, Anxiety, Emotional Distress, Xerosis
Adverse event resulted in: death, disablity
Drug(s) suspected as cause:
Magnevist
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 1999-08-18
End date: 1999-08-18
Magnevist
Omniscan
Omniscan
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging Brain
Start date: 2005-12-06
End date: 2005-12-06
Optimark
Dosage: 30 ml, once
Start date: 2006-03-23
End date: 2006-03-23
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-09-01
End date: 2005-09-01
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Magnevist
Indication: Nuclear Magnetic Resonance Imaging Brain
Omniscan
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2006-05-16
End date: 2006-05-16
Other drugs received by patient: Levothroid; Lotrel; Epogen; Lanoxin; Phoslo; Imuran; Ascorbic Acid W / Folic Acid / Iron / Vitamin B12; Protonix; Acyclovir; Morphine; Reglan; Pravachol; Neurontin; Quinine Sulfate; Imodium; Gastromark; Avinza; Niferex; Coumadin; Lantus; Novolog; Rena-Vite [vit C,vit H,b5,b12,b9,b3,b6,b2,b1 Hcl]; Aciphex; Nephrocaps; Cyclosporine
Possible Optimark side effects in 62 year old male
Reported by a consumer/non-health professional from United States on 2011-11-01
Patient: 62 year old male, weighing 118.0 kg (259.6 pounds)
Reactions: Pain, Cardiac Disorder, Liver Disorder, Depression, Renal Disorder, Pain in Extremity, General Physical Health Deterioration, Skin Disorder, Nephrogenic Systemic Fibrosis, Cerebrovascular Accident, Discomfort, Emotional Distress, Anxiety, Renal Failure, Arthralgia, Skin Fibrosis, Mobility Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Omniscan
Dosage: 20 ml, once
Start date: 2005-11-17
End date: 2005-11-17
Omniscan
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2003-09-05
End date: 2003-09-05
Prohance
Indication: Angiogram
Omniscan
Dosage: 50 ml, once
Indication: Angiogram
Start date: 1999-12-17
End date: 1999-12-17
Magnevist
Dosage: unk unk, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 1996-07-12
End date: 1996-07-12
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Dosage: 10 ml, once
Start date: 2008-03-26
End date: 2008-03-26
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Multihance
Indication: Angiogram
Magnevist
Dosage: 10 ml, once
Indication: Angiogram
Start date: 2006-08-10
End date: 2006-08-10
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Angiogram
Other drugs received by patient: Aspirin [acetylsalicylic Acid,calcium Carbonate,citric Acid]; Hydrochlorothiazide; Metoprolol Tartrate; Enalapril Maleate; Plavix; Vitamin TAB; Lantus; Humalog; Crestor; Metformin HCL; Venlafaxine; Alprazolam
Possible Optimark side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-27
Patient: male, weighing 76.2 kg (167.6 pounds)
Reactions: Emotional Distress, Anhedonia, Arthralgia, Skin Exfoliation, Swelling, Skin Hypertrophy, Nephrogenic Systemic Fibrosis, Extremity Contracture
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: unk
Start date: 2005-06-28
End date: 2005-06-28
Gadolinium IN Unspecified Drug
Indication: Endoscopic Retrograde Cholangiopancreatography
Omniscan
Dosage: 20 ml, unk
Indication: Imaging Procedure
Start date: 2003-11-14
End date: 2003-11-14
Gadolinium IN Unspecified Drug
Gadolinium IN Unspecified Drug
Indication: Nuclear Magnetic Resonance Imaging
Gadolinium IN Unspecified Drug
Magnevist
Dosage: unk
Indication: Imaging Procedure
Start date: 2005-06-17
End date: 2005-06-17
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Arteriogram Coronary
Start date: 1996-05-10
End date: 1996-05-10
Gadolinium IN Unspecified Drug
Indication: Nuclear Magnetic Resonance Imaging Abdominal
Other drugs received by patient: Glucovance; Diovan; Diabeta; Lipitor; Levothyroxine Sodium; Hydrocodone Bitartrate; Carvedilol; Celebrex; Neurontin
Possible Optimark side effects in 60 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-24
Patient: 60 year old male, weighing 118.0 kg (259.6 pounds)
Reactions: Pain, Cardiac Disorder, Liver Disorder, Depression, Renal Disorder, Pain in Extremity, Skin Disorder, General Physical Health Deterioration, Nephrogenic Systemic Fibrosis, Cerebrovascular Accident, Discomfort, Anxiety, Emotional Distress, Renal Failure, Arthralgia, Skin Fibrosis, Mobility Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Magnevist
Dosage: unk unk, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 1996-07-12
End date: 1996-07-12
Prohance
Indication: Angiogram
Prohance
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Omniscan
Dosage: 20 ml, once
Start date: 2005-11-17
End date: 2005-11-17
Multihance
Indication: Nuclear Magnetic Resonance Imaging
Optimark
Indication: Nuclear Magnetic Resonance Imaging
Omniscan
Dosage: 50 ml, once
Indication: Angiogram
Start date: 1999-12-17
End date: 1999-12-17
Omniscan
Dosage: 20 ml, once
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2003-09-05
End date: 2003-09-05
Optimark
Indication: Angiogram
Multihance
Indication: Angiogram
Magnevist
Dosage: 10 ml, unk
Indication: Angiogram
Start date: 2006-08-10
End date: 2006-08-10
Magnevist
Dosage: 10 ml, once
Start date: 2008-03-26
End date: 2008-03-26
Other drugs received by patient: Lantus; Humalog; Hydrochlorothiazide; Venlafaxine; Vitamin TAB; Plavix; Aspirin [acetylsalicylic Acid,calcium Carbonate,citric Acid]; Crestor; Enalapril Maleate; Alprazolam; Metoprolol Tartrate; Metformin HCL
Possible Optimark side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-10-06
Patient: male, weighing 76.2 kg (167.6 pounds)
Reactions: Skin Exfoliation, Pain, Nephrogenic Systemic Fibrosis, Skin Hypertrophy, Emotional Distress, Anhedonia, Arthralgia, Swelling, Extremity Contracture
Adverse event resulted in: death
Drug(s) suspected as cause:
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Arteriogram Coronary
Start date: 1996-05-10
End date: 1996-05-10
Gadolinium IN Unspecified Drug
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2005-06-17
End date: 2005-06-17
Omniscan
Indication: Nuclear Magnetic Resonance Imaging
Magnevist
Indication: Imaging Procedure
Omniscan
Dosage: 20 ml, unk
Indication: Imaging Procedure
Start date: 2003-11-14
End date: 2003-11-14
Optimark
Indication: Imaging Procedure
Gadolinium IN Unspecified Drug
Indication: Endoscopic Retrograde Cholangiopancreatography
Gadolinium IN Unspecified Drug
Dosage: unk
Indication: Nuclear Magnetic Resonance Imaging
Start date: 2005-06-23
End date: 2005-06-23
Gadolinium IN Unspecified Drug
Dosage: unk
Start date: 2005-06-28
End date: 2005-06-28
Other drugs received by patient: Diovan; Celebrex; Glucovance; Lipitor; Carvedilol; Diabeta; Levothyroxine Sodium; Neurontin; Hydrocodone Bitartrate
|